Oraya Therapeutics Inc. completed enrollment in a trial of its experimental device to treat a common cause of blindness and plans another large trial later this year.
The Newark company said the 226-patient study of its iRay device is designed to study both the effectiveness and safety of its radiation therapy of wet age-related macular degeneration, or wet AMD, in conjunction with standard-of-care drug injections into the eye.
No comments:
Post a Comment